| |
| |
|
| Insider
Information: |
Foley Mark J |
| Relationship: |
|
| City: |
Pleasanton |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,036,952 |
|
|
Indirect Shares
|
110,913 |
|
|
| Direct
Value |
$6,687,505 |
|
|
|
Indirect Value
|
$377,104 |
|
|
| Total
Shares |
1,147,865 |
|
|
| Total
Value |
$7,064,609 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
-1.0
|
| Percentage
Gain/Loss : |
 -48.1%
|
-149.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Zeltiq Aesthetics Inc |
ZLTQ |
President and CEO, Dir... |
2017-04-28 |
0 |
2012-04-27 |
0 |
Premium* |
|
|
Revance Therapeutics, Inc. |
RVNC |
CEO, Director |
2024-03-15 |
994,935 |
2024-03-15 |
110,913 |
Premium* |
|
|
Glaukos Corp |
GKOS |
|
2024-02-23 |
33,220 |
2018-05-31 |
0 |
Premium* |
|
|
Si-Bone, Inc. |
SIBN |
|
2020-06-16 |
8,797 |
2020-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2024-03-15 |
4 |
D |
$5.31 |
$108,928 |
D/D |
(20,533) |
994,935 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2024-03-06 |
4 |
B |
$6.98 |
$209,400 |
D/D |
30,000 |
1,015,468 |
2.81 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
70,750 |
985,468 |
0 |
- |
|
| GKOS |
Glaukos Corp |
|
– • – |
2024-02-23 |
4 |
S |
$92.87 |
$423,487 |
D/D |
(4,560) |
33,220 |
0 |
% |
|
| GKOS |
Glaukos Corp |
|
– • – |
2024-02-23 |
4 |
OE |
$7.28 |
$72,750 |
D/D |
10,000 |
37,780 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-12-31 |
4 |
A |
$7.47 |
$1,972 |
D/D |
264 |
914,718 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-08-11 |
4 |
D |
$18.91 |
$908,890 |
D/D |
(48,064) |
914,454 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
122,143 |
962,518 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-08-03 |
4 |
AS |
$22.57 |
$593,151 |
D/D |
(26,279) |
840,375 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-07-03 |
4 |
AS |
$24.94 |
$655,333 |
D/D |
(26,279) |
866,654 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-06-30 |
4 |
A |
$15.61 |
$15,606 |
D/D |
1,000 |
892,933 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-06-09 |
4 |
AS |
$30.72 |
$960,928 |
D/D |
(31,279) |
891,933 |
0 |
% |
|
| GKOS |
Glaukos Corp |
|
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
27,780 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-05-15 |
4 |
S |
$34.55 |
$2,433,725 |
D/D |
(70,447) |
923,212 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-03-15 |
4 |
D |
$30.65 |
$163,702 |
D/D |
(5,341) |
818,010 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2023-03-09 |
4 |
S |
$31.59 |
$2,223,360 |
D/D |
(70,390) |
823,351 |
0 |
% |
|
| GKOS |
Glaukos Corp |
|
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,948 |
24,550 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2022-12-31 |
4 |
A |
$12.18 |
$7,369 |
D/D |
605 |
718,092 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2022-10-13 |
4 |
D |
$26.97 |
$1,328,920 |
D/D |
(49,274) |
717,487 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2022-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
175,649 |
893,741 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2022-06-30 |
4 |
A |
$11.75 |
$11,747 |
D/D |
1,000 |
766,761 |
0 |
- |
|
| GKOS |
Glaukos Corp |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,364 |
21,602 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Executive Officer |
• • – |
2022-03-15 |
4 |
D |
$15.79 |
$52,170 |
D/D |
(3,304) |
765,761 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CEO |
• • – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
175,649 |
993,659 |
0 |
- |
|
| GKOS |
Glaukos Corp |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,486 |
17,238 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
